全文获取类型
收费全文 | 1123篇 |
免费 | 170篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 93篇 |
妇产科学 | 16篇 |
基础医学 | 132篇 |
口腔科学 | 43篇 |
临床医学 | 164篇 |
内科学 | 295篇 |
皮肤病学 | 12篇 |
神经病学 | 39篇 |
特种医学 | 162篇 |
外科学 | 166篇 |
综合类 | 34篇 |
一般理论 | 1篇 |
预防医学 | 46篇 |
眼科学 | 3篇 |
药学 | 22篇 |
中国医学 | 5篇 |
肿瘤学 | 59篇 |
出版年
2022年 | 2篇 |
2021年 | 16篇 |
2020年 | 7篇 |
2019年 | 8篇 |
2018年 | 37篇 |
2017年 | 44篇 |
2016年 | 38篇 |
2015年 | 34篇 |
2014年 | 38篇 |
2013年 | 73篇 |
2012年 | 35篇 |
2011年 | 28篇 |
2010年 | 65篇 |
2009年 | 55篇 |
2008年 | 42篇 |
2007年 | 39篇 |
2006年 | 24篇 |
2005年 | 27篇 |
2004年 | 21篇 |
2003年 | 29篇 |
2002年 | 21篇 |
2001年 | 34篇 |
2000年 | 19篇 |
1999年 | 14篇 |
1998年 | 65篇 |
1997年 | 58篇 |
1996年 | 59篇 |
1995年 | 51篇 |
1994年 | 31篇 |
1993年 | 41篇 |
1992年 | 18篇 |
1991年 | 22篇 |
1990年 | 24篇 |
1989年 | 23篇 |
1988年 | 24篇 |
1987年 | 26篇 |
1986年 | 19篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 16篇 |
1982年 | 3篇 |
1981年 | 16篇 |
1980年 | 8篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 10篇 |
1976年 | 9篇 |
1975年 | 3篇 |
1971年 | 1篇 |
1938年 | 1篇 |
排序方式: 共有1307条查询结果,搜索用时 15 毫秒
1.
A role for decorin in cutaneous wound healing and angiogenesis 总被引:2,自引:0,他引:2
Hannu Järveläinen MD PhD ; Pauli Puolakkainen MD PhD ; Sari Pakkanen MSc ; Eric L. Brown PhD ; Magnus Höök PhD ; Renato V. Iozzo MD ; E.Helene Sage PhD ; Thomas N. Wight PhD 《Wound repair and regeneration》2006,14(4):443-452
Decorin is known to influence tissue tensile strength and cellular phenotype. Therefore, decorin is likely to have an impact on tissue repair, including cutaneous wound healing. In this study, cutaneous healing of both excisional and incisional full‐thickness dermal wounds was studied in decorin‐deficient (Dcn?/?) animals. A statistically significant delay in excisional wound healing in the Dcn?/? mice occurred at 4 and 10 days postwounding and, in incisional wounds at 4, 10, and 18 days when compared with wild‐type (Dcn?/?) controls. Fibrovascular invasion into polyvinylalcohol sponges was significantly increased by day 18 in Dcn?/? mice relative to Dcn+/+ mice. The 18‐day sponge implants in the Dcn?/? mice showed a marked accumulation of biglycan when compared with the corresponding implants in Dcn+/+ mice. Thus, regulated production of decorin may serve as an excellent therapeutic approach for modifying impaired wound healing and harmful foreign body reactions. 相似文献
2.
H Danielson A Kokkola T Kiviluoto J Sirén J Louhimo E Kivilaakso P Puolakkainen 《Scandinavian journal of surgery》2007,96(1):35-40
BACKGROUND: Clinical benefit from extended lymphadenectomy for gastric cancer remains controversial as a considerable variation exists between results of different studies. METHODS: 562 patients were treated at HUCH between 1987-2003, whereof 223 underwent gastrectomy with curative intent. Of these, 114 patients underwent subtotal/total gastrectomy with D1 (standard) lymphadenectomy and 109 patients had D2-3 (extended) lymph node dissection. The clinical outcome of these patients was analysed retrospectively. RESULTS: The incidence of surgical complications was 33.0% in D2-3 and 16.8% in D1 lymphadenectomy groups (p = 0.008). Abscess was the most common complication (11.0%) among D2-3 operated patients and haemorrhage (4.4%) in D1 group. Hospital mortality was 3.7% in D2-3 and 1.8% in D1 group (p = 0.438). The only statistically significant factor influencing the rate of complications was D2-3 lymphadenectomy (OR 2.620, 95% C.I. 1.375 to 4.991). D2-3 was associated with a longer postoperative hospital stay and operation time, greater blood loss and increased need for blood transfusions compared to D1. The 5-year survival was not statistically different between lymphadenectomy groups. CONCLUSION: It is justified to perform a D2-3 gastrectomy in Europe with a acceptable postoperative mortality but with a significant morbidity. Further studies are needed to assess the value of extended lymphadenectomy in gastric cancer. 相似文献
3.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
4.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
5.
6.
7.
臂丛神经根性损伤膈神经移位术对青壮年患者早期呼吸功能的影响 总被引:1,自引:1,他引:0
目的研究臂丛神经损伤膈神经移位术对青壮年患者早期呼吸功能的影响.方法对16例接受膈神经移位治疗的患者,在术前、术后(10 d)进行肺功能指标的比较,同时定期进行门诊随访,观察呼吸系统自觉症状程度.结果13例术后出现了不同程度的供氧不足症状,16例全部出现一侧膈肌抬高,术后第10天肺活量(VC)、肺活量预计值百分数(VC%)分别比术前减少37.98%和26.88%,两者差异有统计学意义(tvc=11.532、tvc%=0,P<0.01).其它项目如残气量(RV)较术前轻度下降,肺总量(TLC)下降值达到术前肺总量的36.49%,残气量/肺总量比值(RV/TLC%)较术前上升了4.75%,上述各指标的差值均有统计学意义.1 s用力呼气量/用力肺活量比值(FEV1/FVC)和术前比基本无改变,但其差值有统计学意义.膈神经移位右侧(10例)与左侧(6例)术前、术后肺活量比较差异有统计学意义.术后随访8个月~2年,所有患者均无明显呼吸困难和胸闷等症状.结论膈神经移位术后对青壮年患者肺容量有较大的丧失,肺通气功能减弱和小气道阻力增加,但其丧失程度在机体自身代偿耐受范围内,不会导致急剧发生的严重呼吸功能障碍.建议对右侧臂丛神经根性损伤的患者,术前进行严格的肺、心功能检查,避免发生较为严重的并发症. 相似文献
8.
9.
Photodynamic therapy (PDT) is a new modality of cancer treatment. It is based on the use of photosensitizing agents and laser light which interact and produce singlet oxygen. This toxic compound destroys malignant tumours while healthy tissue remains intact. The present paper reviews the method of PDT and its possible clinical applications. 相似文献
10.
Clinical value of severity markers in acute pancreatitis. 总被引:2,自引:0,他引:2
Acute pancreatitis is a common digestive disease of which the severity may vary from mild, edematous to severe, necrotizing disease. An improved outcome in the severe form of the disease is based on early identification of disease severity and subsequent focused management of these high-risk patients. However, the ability of clinicians to predict, upon presentation, which patient will have mild or severe acute pancreatitis is not accurate. Prospective systems using clinical criteria have been used to determine severity in patients with acute pancreatitis, such as the Ranson's prognostic signs, Glasgow score, and the acute physiology and chronic health evaluation II score (APACHE II). Their application in clinical practise has been limited by the time delay of at least 48 h to judge all parameters in the former two and by being cumbersome and time-consuming in the latter. Contrast-enhanced computed tomography is presently the most accurate non-invasive single method to evaluate the severity of acute pancreatitis. It cannot, however, be performed to all patients with acute pancreatitis. Therefore, considerable interest has grown in the development of reliable biochemical markers that reflect the severity of acute pancreatitis. In this article we critically appraise current and new severity markers of acute pancreatitis in their ability to distinguish between mild and severe disease and their clinical utility. 相似文献